By Clinical Content Hub Posted by Haymarket’s Clinical Content Hub. The editorial staff of Oncology Nurse Advisor had no role in this content’s preparation Reviewed June 2022
Special Collections
Meeting Insights
Samer Al Hadidi, MD, MS (CRDSA), FACP, a hematologist/oncologist at the Winthrop P. Rockefeller Cancer Institute of the University of Arkansas for Medical Sciences, discusses promising multiple myeloma research presented at the ASH 2021 Annual Meeting, as well as the ethnic disparities that continue to persist in multiple myeloma research and therapy.
Results from ELEVATE-RR demonstrated the potential of alacabrutinib as a possible first-line therapy for CLL, with comparable outcomes to ibrutinib and a somewhat better toxicity profile.
Abhishek Solanki, MD, radiation oncologist at Loyola University Medical Center and associate professor, Director of Clinical Research, and Quality Medical Director at Loyola University Stritch School of Medicine, in Chicago, discusses promising research on the topic of urothelial carcinoma presented at the 2021 Genitourinary Cancers Symposium.
